株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

倦怠感:パイプライン分析

Fatigue - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 192586
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
倦怠感:パイプライン分析 Fatigue - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 40 Pages
概要

倦怠感(疲労感・疲弊・無気力・無感情とも)とは、肉体的または精神的に疲弊して虚弱化した状態のことを表しています。主な徴候・症状として、筋肉痛やリンパ節の痛み、慢性(長期的)疲労、くらみ、頭痛、過敏性、食欲不振などが挙げられます。

当レポートでは、世界各国での倦怠感治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

倦怠感の概要

治療薬の開発

  • 倦怠感向けパイプライン製品:概要
  • 倦怠感向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Biovista Inc.
  • Dimerix Bioscience Pty Ltd
  • Hemispherx Biopharma, Inc.
  • Merz Pharmaceuticals GmbH
  • MultiCell Technologies, Inc.
  • Teva Pharmaceutical Industries Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (lofepramine hydrochloride + phenylalanine)
  • armodafinil
  • DMX-400
  • MRZ-9547
  • rintatolimod
  • Small Molecule for Chronic Fatigue Syndrome

最新パイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Fatigue, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Fatigue - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
  • Fatigue - Pipeline by Helsinn Group, H2 2019
  • Fatigue - Pipeline by K-Pax Pharmaceuticals Inc, H2 2019
  • Fatigue - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019
  • Fatigue - Pipeline by MultiCell Technologies Inc, H2 2019
  • Fatigue - Pipeline by Resolys Bio Inc, H2 2019
  • Fatigue - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Fatigue, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11363IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fatigue - Pipeline Review, H2 2019, provides an overview of the Fatigue (Central Nervous System) pipeline landscape.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fatigue - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 3 and 2 respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fatigue (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fatigue (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fatigue (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fatigue (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fatigue (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fatigue (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fatigue (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatigue - Overview
  • Fatigue - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Fatigue - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fatigue - Companies Involved in Therapeutics Development
    • Aoxing Pharmaceutical Company Inc
    • Helsinn Group
    • K-Pax Pharmaceuticals Inc
    • Merz Pharma GmbH & Co KgaA
    • MultiCell Technologies Inc
    • Resolys Bio Inc
  • Fatigue - Drug Profiles
    • (lofepramine hydrochloride + phenylalanine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anamorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Chronic Pain and Fatigue - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • caffeine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPAX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRZ-9547 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLS-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fatigue - Dormant Projects
  • Fatigue - Product Development Milestones
    • Featured News & Press Releases
      • Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top